




Healthcare Industry News: bone void filler
News Release - May 21, 2007
Medtronic Announces Progenix(TM) DBM Putty
MEMPHIS, Tenn.--(HSMN NewsFeed)--Medtronic, Inc. (NYSE:MDT ), today announced the immediate, nationwide availability of Progenix(TM) DBM Putty, distributed through its wholly-owned subsidiary SpinalGraft Technologies LLC. Progenix DBM Putty is a bone graft substitute and bone void filler used in voids or gaps of the pelvis, ilium, and extremities. Progenix DBM Putty provides excellent handling characteristics while offering surgeons a treatment option with proven bone formation, certified osteoinductivity, validated viral inactivation and device-level sterility.Bone voids or gaps can be surgically created defects or bony defects resulting from traumatic injury. Progenix DBM Putty provides a bone void filler that is resorbed and is replaced by host bone during the healing process.
"I like the fact that Progenix DBM Putty is easy to use, off the shelf, and deliverable directly through a syringe," said Christopher Silveri, M.D., an orthopedic surgeon from Fairfax, Va., who performed some of the first clinical evaluations of the putty. "Based on its handling characteristics and the supporting studies that I have reviewed, the Progenix DBM Putty gives me an excellent bone grafting option for my patients."
"We are pleased to announce this latest addition to our market-leading portfolio of biologic technologies," added Pete Wehrly, senior vice president and president of the Spinal and Biologics business at Medtronic. "Progenix DBM Putty provides our surgeon customers a great option for treating their patients within the bone void filler indication."
About Medtronic's Spinal and Biologics Business
The Spinal and Biologics business at Medtronic is based in Memphis, Tenn. It is the global leader in today's spine market and is committed to advancing the treatment of spinal conditions. The Spinal and Biologics business works with world-renowned surgeons, researchers and innovative partners to offer state-of-the-art products and technologies for neurological, orthopaedic, dental and spinal conditions. Medtronic is committed to developing affordable, minimally-invasive procedures that provide lifestyle-friendly surgical therapies. More information about the company and its treatment therapies can be found at www.medtronicspinal.com and its patient-education Web sites, www.back.com, www.iscoliosis.com, www.maturespine.com and www.necksurgery.com.
About Medtronic
Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology - alleviating pain, restoring health, and extending life for millions of people around the world.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's Annual Report on Form 10-K for the year ended April 28, 2006. Actual results may differ materially from anticipated results.
Source: Medtronic
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
Related News Items
Medtronic appoints Thierry Piéton as Chief Financial OfficerMedtronic Achieves CE Mark Approval for BrainSense Adaptive Deep Brain Stimulation and Electrode Identifier, a Groundbreaking Advance In Personalized, Sensing-Enabled Care for People with Parkinson's Through Innovative Brain-Computer Interface Technology
Medtronic Receives FDA Clearance for New InPen(TM) App, Paving the Way for its Smart MDI System Launch with Simplera(TM) CGM